Barclays Maintains an 'Underweight' on Comerica (CMA); 1Q11 Follow-up: NIM Revised Upward and EPS Beat but Loan Growth Lacking
Tweet Send to a Friend
Barclays maintains an 'Underweight' on Comerica (NYSE: CMA), PT $44.
Barclays analyst says, "Bottom-line, CMA's 1Q11 results exceeded our expectations ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "Bottom-line, CMA's 1Q11 results exceeded our expectations ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
